Interferons, immunity and cancer immunoediting
The DOI matches its Crossref record; 118 of the 119 references it cites were found in a registry or an index.
Abstract
A clear picture of the dynamic relationship between the host immune system and cancer is emerging as the cells and molecules that participate in naturally occurring antitumour immune responses are being identified. The interferons (IFNs) - that is, the type I IFNs (IFNalpha and IFNbeta) and type II IFN (IFNgamma) - have emerged as central coordinators of tumour-immune-system interactions. Indeed, the decade-old finding that IFNgamma has a pivotal role in promoting antitumour responses became the focus for a renewed interest in the largely abandoned concept of cancer immunosurveillance. More recently, type I IFNs have been found to have distinct functions in this process. In this Review, we discuss the roles of the IFNs, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a cytokine which promotes increased tumour immunogenicity and often used to assess T-cell activation31”
From Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis (2016) · cites this paper as [31]
Citations
Cites
1 retracted
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577 · cited 1×
“However, it remains unclear whether the tumour-suppressor functions of RNaseL depend on IFN”
BackgroundRetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Using a combination of histological and gene-expression analyses, Galon et al”
MethodCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Self-citationCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 1×
“These pathways coordinately defend cells from the oncogenic and/or genotoxic stimuli that can lead to malignant transformatio”
BackgroundHOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932 · cited 1×
“Detailed reviews of IFN biology have been published elsewher”
BackgroundSelf-citationMechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citation
Research works printed but not linked: 1
- Yang, J., Murphy, T. L., Ouyang, W. & Murphy, K. M. Induction of interferon-γ production in TH1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur. J. Immunol. 29, 548–555 (1999). · DOI · Paper page
Cited by
Items 301–400 of 1,002
Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma
Choi, J., Beaino, W., Fecek, R. J., Fabian, K. P., Laymon, C. M., Kurland, B. F., Storkus, W. J., & Anderson, C. J. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.209510 · Cited by 103
“CD8positive T cells and natural killer cells are both well appreciated for their abilities to prevent or limit cancer metastasis (39,40).”
BackgroundLipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad
Bleve, A., Durante, B., Sica, A., & Consonni, F. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165845 · Cited by 111
Early tumor dissemination, but late metastasis: insights into tumor dormancy
Röcken, M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43424 · Cited by 101
Cytokine Regulation of Metastasis and Tumorigenicity
Yao, M., Brummer, G., Acevedo, D. S., & Cheng, N. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.05.005 · Cited by 106
Shah, D. J., & Dronca, R. S. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.02.002 · Cited by 96
The Dual Role of Inflammation in Colon Carcinogenesis
Monteleone, G., Pallone, F., & Stolfi, C. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130911071 · Cited by 109
Yin, T., Wang, G., He, S., Liu, Q., Sun, J., & Wang, Y. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.11.009 · Cited by 104
Chapter 7 IFN Inducibility of Major Histocompatibility Antigens in Tumors
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)00407-7 · Cited by 93
“The multiple activities of IFNs on tumor cells might coordinate the antitumor immune responses so that the early recognition and/or elimination of cancer cells by the innate immune system transitions to immune attack by the adaptive immune system (Dunn et al., 2006) .”
InfluentialViral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses
Molino, N. M., Neek, M., Tucker, J. A., Nelson, E. L., & Wang, S. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.056 · Cited by 107
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
Valeri, A., García-Ortiz, A., Castellano, E., Córdoba, L., Maroto-Martín, E., Encinas, J., Leivas, A., Río, P., & Martínez‐López, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953849 · Cited by 103
“Additionally, NK cells efficiently produce cytokines and chemokines that modulate other immune mediators of cytotoxicity (31).”
BackgroundOncolytic myxoma virus: The path to clinic
Chan, W. M., Rahman, M. M., & McFadden, G. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.056 · Cited by 102
Gao, J., Senthil, M., Ren, B., Yan, J., Xing, Q., Yu, J., Zhang, L., & Yim, J. H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.156 · Cited by 99
“In AGS, this may be a mechanism of cancer cell evasion from tumor immunosurveillance, as has been shown in numerous cancer cell lines.(29) Although gene therapy with IRF-1 would be one option for treatment, other modes of upregulation or activation of IRF-1 independent of Stat1 expression are possible.”
Baltz, K. M., Krusch, M., Bringmann, A., Brossart, P., Mayer, F., Kloss, M., Baessler, T., Kumbier, I., Peterfi, A., Kupka, S., et al. (2007) · The FASEB Journal · doi:10.1096/fj.06-7724com · Cited by 99
“To eradicate developing tumors, NK cells must perform two critical tasks—namely, cytotoxicity and production of IFN-—the latter participating in cancer elimination by inhibiting cellular proliferation and angiogenesis, promoting apoptosis, and stimulating the adaptive immune system ( 40 ).”
BackgroundAllergoOncology – the impact of allergy in oncology: EAACI position paper
Jensen‐Jarolim, E., Bax, H. J., Bianchini, R., Capron, M., Corrigan, C., Castells, M., Dombrowicz, D., Daniels‐Wells, T. R., Fazekas, J., Fiebiger, E., et al. (2017) · Allergy · doi:10.1111/all.13119 · Cited by 96
“Th1 cells produce interferon-gamma (IFN-c) which mediates antitumour activity by several mechanisms, including activation of macrophages, enhancement of antigen processing and presentation, and inhibition of angiogenesis (71).”
BackgroundRodríguez, T., Méndez, R., Campo, A. D., Jiménez, P., Aptsiauri, N., Garrido, F., & Ruiz‐Cabello, F. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-34 · Cited by 111
“On entering the nucleus, ISGF3 binds IFN-stimulate response elements (ISREs) [10].”
BackgroundMutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 94
γδ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion
Presti, E. L., Pizzolato, G., Corsale, A. M., Caccamo, N., Sireci, G., Dieli, F., & Meraviglia, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01395 · Cited by 103
“There are at least three major γδ T cell subsets in humans that exhibit different Vδ chain in the TCR: (1) the population expressing the Vδ2 gene paired with the Vγ9 chain (Vγ9Vδ2 T cells) represent the majority of circulating γδ T cell population; (2) the population expressing the Vδ1 gene and different Vγ chain, are…”
BackgroundInfluentialRazaghi, A., Owens, L., & Heimann, K. (2016) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2016.10.022 · Cited by 103
Bartee, E., Mohamed, M. R., López, M. C., Baker, H. V., & McFadden, G. (2008) · Journal of Virology · doi:10.1128/jvi.01376-08 · Cited by 104
Tumor Immunotherapy by Epicutaneous Immunization Requires Langerhans Cells
Stoitzner, P., Green, L. K., Jung, J. Y., Price, K. M., Tripp, C. H., MALISSEN, B., Kissenpfennig, A., Hermans, I. F., & Ronchese, F. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1991 · Cited by 94
Bill, M. A., Bakan, C. E., Benson, D. M., Fuchs, J. R., Young, G. S., & Lesinski, G. B. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0377 · Cited by 97
Umemoto, Y., Okano, S., Matsumoto, Y., Nakagawara, H., Matono, R., Yoshiya, S., Yamashita, Y., Yoshizumi, T., Ikegami, T., Soejima, Y., et al. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-014-0933-3 · Cited by 93
“Cancer cell acquisition of an immune evasion mechanism during tumor progression while under immunosurveillance is called cancer immunoediting [21].”
BackgroundInhibiting the inhibitors: evaluating agents targeting cancer immunosuppression
Whiteside, T. L. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.482207 · Cited by 95
“It has been suggested that the immune system might drive these antigenic changes via ‘immune editing’ by eliminating those malignant cells that are sensitive to immune intervention and allowing for the selection and survival of immunoresistant variants [13].”
BackgroundCurrent status of skin cancers with a focus on immunology and immunotherapy
Kohnehshahri, M. K., Sarkesh, A., Khosroshahi, L. M., HajiEsmailPoor, Z., Aghebati‐Maleki, A., Yousefi, M., & Maleki, L. A. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03012-7 · Cited by 100
“Adaptive immunity has a criti - cal role in tumor eradication or proliferation depending on the environmental signals [69, 80].”
BackgroundIwata, S., Mikami, Y., Sun, H.-W., Brooks, S. R., Jankovic, D., Hirahara, K., Onodera, A., Shih, H.-Y., Kawabe, T., Jiang, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.05.005 · Cited by 90
“T helper 1 (Th1) cells and their product IFN-g (type II IFN) are essential for resistance to pathogens, especially intracellular bacteria and parasites (Dunn et al., 2006; Sallusto, 2016; Zhu et al., 2010).”
Cell Surface CD74–MIF Interactions Drive Melanoma Survival in Response to Interferon-γ
Tanese, K., Hashimoto, Y., Berkova, Z., Wang, Y., Samaniego, F., Lee, J. E., Ekmekcioglu, S., & Grimm, E. A. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.204 · Cited by 93
“Interferon-γ (IFN-γ), a cytokine produced by immune cells, plays a crucial role in cancer immune surveillance, promoting antitumor responses (Dunn et al., 2006).”
BackgroundNecroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy
Meng, M.-B., Wang, H.-H., Cui, Y.-L., Wu, Z.-Q., Shi, Y., Zaorsky, N. G., Deng, L., Yuan, Z., Lü, Y., & Wang, P. (2016) · Oncotarget · doi:10.18632/oncotarget.10548 · Cited by 106
“For example, IFN-α/β predominantly affects macrophages, DCs, and natural killer (NK) cells; inducing their activation and/ or maturation, upregulating of chemokine expression, enhancing antigen-presentation and cross-presentation by DCs and a robustly augmenting induction of adaptive immune responses [107].”
BackgroundSpleen-Targeted mRNA Vaccine Doped with Manganese Adjuvant for Robust Anticancer Immunity In Vivo
Luo, Z., Lin, Y., Meng, Y., Li, M., Ren, H., Shi, H., Cheng, Q., & Wei, T. (2024) · ACS Nano · doi:10.1021/acsnano.4c09902 · Cited by 94
Li, Q., Zhang, X., Zhang, C., Zhang, Y., Niu, M., Chen, Z., Zhang, S., He, J., Chen, W., & Zhang, X.-Z. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c05148 · Cited by 92
Plasmacytoid dendritic cells and cancer
Vermi, W., Soncini, M., Melocchi, L., Sozzani, S., & Facchetti, F. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0411190 · Cited by 97
The function of natural compounds in important anticancer mechanisms
Nan, Y., Su, H., Zhou, B., & Liu, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1049888 · Cited by 98
“There are seven proteins in the STAT family, among which STAT1 and STAT2 play an important role in antitumor immune response, STAT3 and STAT5 are related to tumorigenesis, especially STAT3 is closely related to cancer cell survival, immunosuppression, and persistent inflammation (94).”
BackgroundInfluentialFAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer
Canel, M., Sławińska, A., Lonergan, D. W., Kallor, A. A., Upstill‐Goddard, R., Davidson, C., von Kriegsheim, A., Biankin, A. V., Byron, A., Alfaro, J. A., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-327927 · Cited by 95
“16 Expression of Major Histocompatibility Complex class-I (MHC-I), which is induced in response to IFN γ , is often downregulated in tumours, resulting in immune evasion due to a lack of antigen presentation.”
BackgroundSamten, B., Townsend, J. C., Weis, S. E., Bhoumik, A., Klucar, P., Shams, H., & Barnes, P. F. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.2056 · Cited by 100
“I FN- , produced primarily by T cells and NK cells in response to microbial infection, plays an important role in protection against many pathogens, including intracellular bacteria such as Mycobacterium tuberculosis (1, 2), viruses (3), fungi (4), and protozoa (5) and in immune surveillance to prevent development of…”
BackgroundHarnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs
Capuano, C., Pighi, C., Battella, S., Federicis, D. D., Galandrini, R., & Palmieri, G. (2021) · Cancers · doi:10.3390/cancers13102500 · Cited by 90
The Janus face of dendritic cells in cancer
Chaput, N., Conforti, R., Viaud, S., Spatz, A., & Zitvogel, L. (2008) · Oncogene · doi:10.1038/onc.2008.270 · Cited by 96
Ni, J., Hölsken, O., Miller, M., Hammer, Q., Luetke-Eversloh, M. V., Romagnani, C., & Cerwenka, A. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1219009 · Cited by 97
“IFNg is a critical cytokine involved in cancer immunosurveillance.(32,33) Accordingly, we observed that adoptive transfer of IL-12/15/18-pretreated IFNg-deficient NK cells failed to control tumor growth.”
BackgroundRožman, P. J., & Švajger, U. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.04.001 · Cited by 95
Bernstein, M. B., Garnett‐Benson, C., Zhang, H., Velcich, A., Wattenberg, M. M., Gameiro, S. R., Kalnicki, S., Hodge, J. W., & Guha, C. (2014) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2013.1578 · Cited by 91
“9 10–12 Interestingly, the first FDA-approved cancer vaccine was PROVENGE (cid:2) for treatment of PCa.”
Garrido, F., Perea, F., Bernal, M., Sánchez‐Palencia, A., Aptsiauri, N., & Ruiz‐Cabello, F. (2017) · Vaccines · doi:10.3390/vaccines5010007 · Cited by 89
Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways
Taghiloo, S., & Asgarian‐Omran, H. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103164 · Cited by 93
Singh, K., Coburn, L. A., Asim, M., Barry, D. P., Allaman, M. M., Shi, C., Washington, M. K., Luis, P. B., Schneider, C. G., Delgado, A. G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0116 · Cited by 87
“3A) in the innate cytokines CSF2 (GM-CSF), TNFa, IL-1a, and IL-1b, as well as the prototype Th1 cytokine IFNg , and the chemokines CXCL2 (MIP2), CXCL9 (MIG), CXCL10 (IP-10), CCL2 (MCP-1), CCL3 (MIP-1a), CCL4 (MIP-1b), and CCL5 (RANTES).”
BackgroundInfluentialLow risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis
Zenouzi, R., Weismüller, T. J., Hübener, P., Schulze, K., Bubenheim, M., Pannicke, N., Weiler–Normann, C., Lenzen, H., Manns, M. P., Lohse, A. W., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.02.008 · Cited by 86
Next-generation cytokines for cancer immunotherapy
Xue, D., Hsu, E. J., Fu, Y., & Peng, H. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab014 · Cited by 96
Bourquin, C., Hotz, C., Noerenberg, D., Voelkl, A., Heidegger, S. M., Roetzer, L. C., Storch, B., Sandholzer, N., Wurzenberger, C., Anz, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3903 · Cited by 86
“Both the cytokines IFN-a and IL-12 are believed to play central roles in the immunologic control of cancer (31, 32).”
BackgroundDelayed apoptosis of tumor associated neutrophils in the absence of endogenous IFN‐β
Andzinski, L., Wu, C., Lienenklaus, S., Kröger, A., Weiss, S., & Jablonska, J. (2015) · International Journal of Cancer · doi:10.1002/ijc.28957 · Cited by 81
The role of BST‐2/Tetherin in host protection and disease manifestation
Mahauad‐Fernandez, W. D., & Okeoma, C. M. (2015) · Immunity Inflammation and Disease · doi:10.1002/iid3.92 · Cited by 86
“As the interaction between BST-2 and ILT7 suppress pDCs-mediated IFN responses required for deterring tumor growth [151, 152], it is tempting to speculate that elevated BST-2 in tumors [119, 131, 153] and engagement of ILT7 by BST-2 may contribute to tumor tolerance and progression.”
BackgroundKallert, S. M., Darbre, S., Bonilla, W. V., Kreutzfeldt, M., Page, N., Müller, P., Kreuzaler, M., Lu, M., Favre, S., Kreppel, F., et al. (2017) · Nature Communications · doi:10.1038/ncomms15327 · Cited by 88
Emerging biomarkers for immune checkpoint inhibition in lung cancer
Cyriac, G., & Gandhi, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.006 · Cited by 89
Yu, F., Ng, S. S., Chow, B., Sze, J., Lü, G., Poon, W. S., Kung, H., & Lin, M. C.-M. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0377-4 · Cited by 90
“where the cancer cells escape the mechanisms that operate to suppress them and they become clinically detectable and grow progressively [24, 25].”
BackgroundStrategies to counteract MHC-I defects in tumors
Lampen, M. H., & van Hall, T. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.12.005 · Cited by 85
“The apparent selection and outgrowth of tumor variants with low MHC-I expression might represent a sign of immunoediting by which an active immune system shapes tumor phenotypes [2,3].”
BackgroundArmeanu, S., Krusch, M., Baltz, K. M., Weiß, T. S., Smirnow, I., Steinle, A., Lauer, U. M., Bitzer, M., & Salih, H. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4744 · Cited by 95
“To eradicate tumors, NK cells perform two critical tasks, namely cytotoxicity and production of IFN-g , the latter participating in cancer elimination by e.g., inhibiting cellular proliferation and angiogenesis, promoting apoptosis, and stimulating the adaptive immune system (32).”
Structural analysis of cytokines comprising the IL-10 family
Zdanov, A. S. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2010.08.003 · Cited by 98
Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy
Fuchs, S. Y. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2012.0117 · Cited by 80
Zhao, L., Wang, W., Huang, S., Yang, Z., Xu, L., Yang, Q., Zhou, X., Wang, J., Shen, Q., Wang, C., et al. (2018) · Genome biology · doi:10.1186/s13059-018-1412-6 · Cited by 92
“However, cancers and their metastatic derivatives could evolve to overcome these immune mechanisms partly through the recruitment of immunosuppressive cells and inactivation of tumor-killing cells [6].”
Hiltbrunner, S., Cords, L., Kasser, S., Freiberger, S. N., Kreutzer, S., Toussaint, N. C., Grob, L., Opitz, I., Messerli, M., Zoche, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40745-5 · Cited by 90
Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities
Wang, H., Niu, X., Jin, Z., Zhang, S., Fan, R., Xiao, H., & Hu, S. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03519-z · Cited by 94
Dijkgraaf, E. M., Santegoets, S. J. A. M., Reyners, A. K. L., Goedemans, R., Nijman, H. W., van Poelgeest, M. I. E., van Erkel, A. R., Smit, V. T. H. B. M., Daemen, T. A. H. H., van der Hoeven, J. J. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4772 · Cited by 83
“144 cross-presentation of tumor antigens and to enhance survival of activated T cells, thereby enhancing the anti-tumor response [25-30].”
BackgroundKübler, K., Gehrke, N., Riemann, S., Böhnert, V., Zillinger, T., Hartmann, E., Pölcher, M., Rudlowski, C., Kuhn, W. C., Hartmann, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0825 · Cited by 98
“Consequentially, EOC cell apoptosis triggered by pathways of virus detection is able to strongly activate human phagocytic cells that then secrete IFN-α, whose pleiotropic antiviral effects promote antitumor activity (42).”
BackgroundStochastic model for tumor growth with immunization
Bose, T., & Trimper, S. (2009) · Physical Review E · doi:10.1103/physreve.79.051903 · Cited by 91
Barber, A., Zhang, T., & Sentman, C. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.72 · Cited by 84
IL-17 Suppresses Immune Effector Functions in Human Papillomavirus-Associated Epithelial Hyperplasia
Gosmann, C., Mattarollo, S. R., Bridge, J. A., Frazer, I. H., & Blumenthal, A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400216 · Cited by 86
Nonomura, Y., Otsuka, A., Nakashima, C., Seidel, J. A., Kitoh, A., Dainichi, T., Nakajima, S., Sawada, Y., Matsushita, S., Aoki, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1248327 · Cited by 83
Therapeutic applications of TRAIL receptor agonists in cancer and beyond
Amarante-Mendes, G. P., & Griffith, T. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.09.001 · Cited by 92
“(Dunn et al., 2006; Swann et al., 2007; Fuertes et al., 2011), as well as modulate the apoptosis signaling pathway (Kayagaki et al.”
Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus
Miles, L. A., Burga, L. N., Gardner, E. E., Bostina, M., Poirier, J. T., & Rudin, C. M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93472 · Cited by 90
“The potency of cellular antiviral responses is similarly variable in normal and cancerous cells (14, 15).”
BackgroundThe Radiobiology of Radiopharmaceuticals
Morris, Z. S., Wang, A. Z., & Knox, S. J. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.07.002 · Cited by 83
TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review
Komal, A., Noreen, M., & El-kott, A. F. (2021) · Immunologic Research · doi:10.1007/s12026-021-09203-6 · Cited by 83
Double-edged effects of interferons on the regulation of cancer-immunity cycle
Zhang, X., Wang, S., Zhu, Y., Zhang, M., Zhao, Y., Yan, Z., Wang, Q., & Li, X. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1929005 · Cited by 85
“Both subunits of IFNGR are ubiquitously expressed in all mammalian cells.24,25 The type III IFNs consist of IFN-λ1 (IL-29), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B), and IFN-λ4, and this type of IFN binds to the heterodimeric receptor composed of IFNLR1 (also known as IL28RA) and IL10RB.19 Although the expression of IL10RB is…”
BackgroundInfluentialKrug, J., Rodrian, G., Petter, K., Yang, H., Khoziainova, S., Guo, W., Bénard, A., Merkel, S., Gellert, S., Maschauer, S., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.11.018 · Cited by 86
Zhang, T., Barber, A., & Sentman, C. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2251 · Cited by 85
“Tumor cells are also known to mutate (15); therefore, induction of polyclonal tumor–specific T cells will minimize the”
Loss of Connectivity in Cancer Co-Expression Networks
Anglani, R., Creanza, T. M., Liuzzi, V. C., Piepoli, A., Panza, A., Andriulli, A., & Ancona, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087075 · Cited by 93
“Our findings confirm the requirement of a deeper understanding of the functions of these molecules in order to identify additional targets for new immunotherapeutic strategies that will aim to interfere with undesidered immune responses [51,52].”
BackgroundDu, L., Xiao, X., Wang, C., Zhang, X., Zheng, N., Wang, L., Zhang, X., Li, W., Wang, S., & Dong, Z. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01951.x · Cited by 82
IFITM1 promotes the metastasis of human colorectal cancer via CAV-1
Yu, F., Xie, D., Ng, S. S., Lum, C. T., Cai, M.-Y., Cheung, W. K. W., Kung, H., Lin, G., Wang, X., & Lin, M. C.-M. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.034 · Cited by 85
Gamma Interferon-Induced Guanylate Binding Protein 1 Is a Novel Actin Cytoskeleton Remodeling Factor
Ostler, N., Britzen‐Laurent, N., Liebl, A., Naschberger, E., Lochnit, G., Ostler, M., Forster, F., Kunzelmann, P., Ince, S., Supper, V., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00664-13 · Cited by 88
Tymoszuk, P., Charoentong, P., Hackl, H., Spilka, R., Müller-Holzner, E., Trajanoski, Z., Obrist, P., Revillion, F., Peyrat, J.-P., Fiegl, H., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-257 · Cited by 79
“It has been postulated from these observations that tumors may adapt to the anti-tumor action of STAT1 by down-regulating its expression and/or by impairing its activation [1].”
BackgroundLoumagne, L., Baudhuin, J., Favier, B., Montespan, F., Carosella, E. D., & Rouas‐Freiss, N. (2014) · International Journal of Cancer · doi:10.1002/ijc.28845 · Cited by 83
“It is now well accepted that both innate and adaptive immune systems protect the host against the development of cancer.(1) However, tumor cells circumvent such immunosurveillance through the outgrowth of poorly immunogenic variants and subversion of the immune system by multiple immunosuppressive mechanisms such as i…”
BackgroundMori, K., Haraguchi, S., Hiori, M., Shimada, J., & Ohmori, Y. (2015) · BMC Cancer · doi:10.1186/s12885-015-1587-0 · Cited by 80
“Taken together, these results suggest that the persistent IFN-stimulating environment from the premalignant to malignant lesion may allow tumor cells to acquire resistance to the antitumor responses of IFNs via cancer immunoediting [55].”
BackgroundEnhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors
MacTavish, H., Diallo, J., Huang, B., Stanford, M. M., Bœuf, F. L., Silva, N. D., Cox, J. A., Simmons, J.-G., Guimond, T., Falls, T. J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014462 · Cited by 84
Huang, W., & Lin, C. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.12.024 · Cited by 82
Regulatory T cells and immune tolerance to tumors
Cao, X. (2009) · Immunologic Research · doi:10.1007/s12026-009-8124-7 · Cited by 84
“At the molecular level, interferons help to prevent tumor formation or influence the immunogenicity of tumors [1, 11], while the perforin/granzyme pathway and the Fas/FasL pathway account for contactmediated cytotoxicity delivered by NK and CD8 T cells [12, 13].”
BackgroundBaessler, T., Krusch, M., Schmiedel, B. J., Kloss, M., Baltz, K. M., Wacker, A., Schmetzer, H. M., & Salih, H. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2650 · Cited by 84
“IFN-g plays a crucial role in tumor immunoediting and participates in cancer elimination by inhibiting cellular proliferation and angiogenesis, promoting apoptosis, and stimulating the adaptive immune system and is instrumental for enhancing antigen processing and presentation for optimal recognition of tumor cells by…”
BackgroundAntonarakis, E. S., Kibel, A. S., Yu, E. Y., Karsh, L. I., Elfiky, A. A., Shore, N. D., Vogelzang, N. J., Corman, J. M., Millard, F. E., Maher, J. C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1780 · Cited by 79
“As tumors progress, the microenvironment becomes increasingly resistant to an immune response (28).”
BackgroundTelltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer
Lei, Y. L., Xie, Y., Tan, Y. S., Prince, M. E., Moyer, J. S., Nor, J. E., & Wolf, G. T. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.08.003 · Cited by 82
“In fact, implantation of tumors in IFN-I receptor-deficient Ifnar1−/− mice lead to significantly increased tumor burden [45].”
BackgroundCombès, E., Andrade, A. F., Tosi, D., Michaud, H., Coquel, F., Garambois, V., Désigaud, D., Jarlier, M., Coquelle, A., Pasero, P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2807 · Cited by 78
Chimeric NKG2D receptor–expressing T cells as an immunotherapy for multiple myeloma
Barber, A., Zhang, T., Megli, C., Wu, J., Meehan, K. R., & Sentman, C. L. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.04.010 · Cited by 78
Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells
Menter, T., & Tzankov, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00054 · Cited by 84
“While immune-deficient nude mice, which display a markedly reduced amount of T-cells, do not show an increased rate of tumors (4), specifically genetically modified mice with knock-outs of recombination activating gene 2, signal transducer and activator of transcription 1 (STAT1); or the gamma-interferon receptor show…”
BackgroundSwaminathan, S., Hansen, A. S., Heftdal, L. D., Dhanasekaran, R., Deutzmann, A., Mahauad‐Fernandez, W. D., Liefwalker, D. F., Horton, C. E., Mosley, A. R., Liebersbach, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16447-7 · Cited by 80
The ‘kiss of death’ by dendritic cells to cancer cells
Chan, C. W., & Housseau, F. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402235 · Cited by 81
Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses
de Souza, A. P. D., & Bonorino, C. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.88 · Cited by 85
Role of Type I and II Interferons in Colorectal Cancer and Melanoma
Franco, S. D., Turdo, A., Todaro, M., & Stassi, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00878 · Cited by 87
“Schreiber and colleagues published an excellent review about the role of IFNs in the different steps of anti-tumor immunity in 2006 (8).”
BackgroundInfluentialIFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer
Imai, D., Yoshizumi, T., Okano, S., Itoh, S., Ikegami, T., Harada, N., Aishima, S., Oda, Y., & Maehara, Y. (2019) · Journal of Surgical Research · doi:10.1016/j.jss.2019.02.038 · Cited by 83
Vahidian, F., Duijf, P. H. G., Safarzadeh, E., Derakhshani, A., Baghbanzadeh, A., & Baradaran, B. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.004 · Cited by 75
Kohara, H., Kitaura, H., Fujimura, Y., Yoshimatsu, M., Morita, Y., Eguchi, T., Masuyama, R., & Yoshida, N. (2011) · Immunology Letters · doi:10.1016/j.imlet.2011.02.017 · Cited by 75
Multilevel omic data integration in cancer cell lines: advanced annotation and emergent properties
Liu, Y., Devescovi, V., Chen, S., & Nardini, C. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-14 · Cited by 72
“Also, inflammation mediated immunity, like Interferon or other cytokines stimulation, plays a central role in response to the therapy since it regulates the expression of genes in the antigen presentation signaling [63].”
BackgroundCohen, M., Elkabets, M., Perlmutter, M., Porgador, A., Voronov, E., Apte, R. N., & Lichtenstein, R. G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001635 · Cited by 73
Gade, P., Roy, S. K., Li, H., Nallar, S. C., & Kalvakolanu, D. V. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00784-07 · Cited by 88
“The interferon (IFN) family of cytokines regulates a number of physiological responses including innate defenses against viral, bacterial, and parasitic pathogens; the development of neoplastic growth; and specific immunity (6, 21, 28, 31, 74, 78).”
BackgroundTumor Restrictions to Oncolytic Virus
Vähä-Koskela, M. J. V., & Hinkkanen, A. (2014) · Biomedicines · doi:10.3390/biomedicines2020163 · Cited by 84
“Transformed cells undergo selective elimination by the immune system before becoming cancerous, termed immunoediting, based on observations of differential capacity of immunocompetent mice to reject tumors previously grown in immunocompromised hosts versus syngeneic animals [80] .”
BackgroundLucarini, V., Buccione, C., Ziccheddu, G., Peschiaroli, F., Sestili, P., Puglisi, R., Mattia, G., Zanetti, C., Parolini, I., Bracci, L., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.08.024 · Cited by 77
“IFN-I play a crucial role in cancer immunoediting and immunosurveillance (Diamond et al., 2011; Dunn et al., 2006; Fuertes et al., 2011) and are endowed with potent ability to activate dendritic cells, natural killer, and CD8 T cell responses and to dampen immunosuppressive activities of regulatory…”
BackgroundMolecularly targeted therapies in cancer: a guide for the nuclear medicine physician
Lheureux, S., Denoyelle, C., Ohashi, P. S., Bono, J. S. D., & Mottaghy, F. M. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3695-3 · Cited by 81
“demonstrated in preclinical models [119].”
Yang, X., Yu, T., Zeng, Y., Lian, K., Zhou, X., Ke, J., Li, Y., Yuan, H., & Hu, F. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00518 · Cited by 73
Li, Q., & Tainsky, M. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028683 · Cited by 73
“The impairment of IFN signaling is linked to an enhanced risk of tumor development [10,11,12] as the IFN pathway also exhibits antiproliferative and immune surveillance activities against cancer.”
Background
Metadata
- Authors
- Dunn, G. P., Koebel, C. M., & Schreiber, R. D.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Schreiber, Robert D.
- Venue
- Nature Reviews Immunology
- Published
- 2006-11
- Volume
- 6
- Issue
- 11
- Pages
- 836-848
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2052313621
- Cited by
- 1,617
- References
- 119
- Citations by year
- 2026: 33 · 2025: 51 · 2024: 87 · 2023: 104 · 2022: 84 · 2021: 94 · 2020: 93 · 2019: 73 · 2018: 85 · 2017: 74 · 2016: 93 · 2015: 100 · 2014: 100 · 2013: 79 · 2012: 76
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- interferon, type I interferon, interferon-gamma, cancer immunoediting, tumor surveillance, antitumor immunity, tumor-immune interactions, interferon-alpha, interferon-beta, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunity, Immunotherapy, Interferons, Neoplasms, Monitoring, Immunologic, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.